Sign up for Table of Contents Alerts.
Email this page
Print this page
Clinical Case Report
Long Term Responses with Cetuximab Therapy in Glioblastoma Multiforme
Cristóbal Belda-Iniesta, Javier de Castro Carpeño, Enrique Casado Saenz, Manuel Gutiérrez, Rosario Perona and Manuel González Barón
volume 5 | issue 8
august 2006Pages: 912 - 914
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Glioblastoma multiforme (GBM) is responsible for most of the deaths associated with primary brain tumors. Standard treatment includes maximal surgical resection followed by chemotherapy and concomitant radiotherapy. Most patients, however, recur shortly after treatment. Second line treatment has little efficacy and the majority of patients die soon from the disease. Recent advances in molecular biology have implicated the epidermal growth factor receptor (EGFR) signaling pathways in the progression and resistance to standard therapies for GBM. This has prompted the evaluation of EGFR tyrosine- kinase inhibitors with encouraging results. Cetuximab is a monoclonal antibody targeted against the extracellular domain of the EGFR with activity against different tumor types, either alone or in combination with chemotherapy and/or radiation therapy. Here we describe three patients with recurrent, heavily-pretreated, EGFR expressing GBM who responded to treatment with single agent cetuximab.
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDFIf the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.